Development of analytical technology in pharmacogenetic research

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 1, 2004, Pages 133-140

  Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Genotype; Mutation detection; Pharmacogenetics; Phenotype; Polymerase chain reaction

Indexed keywords

4 AMINOBENZOIC ACID; 6 HYDROXYHYDROCORTISONE; CAFFEINE; CHLORZOXAZONE; COUMARIN; DEBRISOQUINE; DEXTROMETHORPHAN; DIGOXIN; ERYTHROMYCIN; HYDROCORTISONE DERIVATIVE; MEPHENYTOIN; METOPROLOL; MIDAZOLAM; OMEPRAZOLE; SPARTEINE; TOLBUTAMIDE; TRIMETHYLAMINE; UNCLASSIFIED DRUG;

DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MEASUREMENT; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; QUALITY CONTROL; REVIEW;

ANIMALS; GENOTYPE; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RESEARCH DESIGN; XENOBIOTICS;

EID: 0742269415     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-003-0794-4     Document Type: Review

References (64)

1. Alderborn A, Kristofferson A, Hammerling U (2000) Determination of single-nucleotide polymorphisms by real-time pyrophosphate sequencing. Genome Res 10:1249-1258
2. Alwaiz M, Ayesh R, Mitchell SC, Idle JR, Smith RL (1989) Trimethylaminuria - the detection of carriers using a trimethylamine load test. J Inherit Metab Dis 12:80-85
3. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, Gonzalez FJ (1989) Cytochrome P450 hPCN3, a novel cytochrome P450 IIA gene product that is differentially expressed in adult human liver. J Biol Chem 264:10388-10395
4. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14:1689-1694
5. Campbell ME, Spielberg SP, Kalow W (1987) A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 42:157-165
6. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 22:231-238
7. Cascorbi I, Roots I (1999) Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 9:123-127
8. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-363
9. Chen SQ, Chou WH, Blouin RA, Mao ZP, Humphries LL, Meek C, Neill JR, Martin WL, Hays LR, Wedlund PJ (1996) The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 60:522-534
10. Cholerton S, Idle ME, Vas A, Gonzalez FJ, Idle JR (1992) Comparison of a novel thin-layer chromatographic-flourescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J Chromatogr 575:325-330
11. Cotton RGH (1997) Slowly but surely towards better scanning for mutations. Trends Genet 13:43-46
12. Cribb AE, Isbrucker R, Levatte T, Tsui B, Gillespie CT, Renton KW (1994) Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 4:166-170
13. Daly AK, Steen VM, Fairbrother KS, Idle JR (1996) CYP2D6 multiallelism. Meth Enzymol 272:199-210
14. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 17:153-155
15. Evans DAP, Storey PB, McKusick VA (1960) Genetic control of isoniazid metabolism in man. Br Med J 2:485-491
16. Fuhr U, Rost K (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva. Pharmacogenetics 4:109-116
17. Gillam EMJ, Guo Z, Ueng Y-F, Yamazaki H, Cock I, Reilly PEB, Hooper WD, Guengerich FP (1995) Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 317:374-384
18. Grant DM, Tang BK, Kalow W (1983) Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 33:355-359
19. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R (1997) Human acetyltransferase polymorphisms. Mutat Res 376:61-70
20. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, VonRichter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153
21. Hallier E, Langhof T, Dannappel D, Leutbecher M, Schroder K, Goergens HW, Muller A, Bolt HM (1993) Polymorphism of glutathione conjugation of methyl-bromide, ethylene-oxide and dichloromethane in human blood - influence on the induction of sister chromatid exchanges (SCE) in lymphocytes. Arch Toxicol 67:173-178
22. Hoffmeyer S, Burk O, vonRichter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
23. Hongyo T, Buzard GS, Calvert RJ, Weghorst CM (1993) Cold SSCP - a simple, rapid and nonradioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acid Res 21:3637-3642
24. Howell WM, Jobs M, Gyllensten U, Brookes AJ (1999) Dynamic allele-specific hybridization - a new method for scoring single nucleotide polymorphisms. Nat Biotech 17:87-88
25. Hukkanen J, Hakkola J, Anttila S, Piipari R, Karjalainen A, Pelkonen O, Raunio H (1997) Detection of mRNA encoding xenobiotic-metabolizing cytochrome P450 s in human bronchoalveolar macrophages and peripheral blood lymphocytes. Mol Carcinog 20:224-230
26. Idle JR, Mahgoub A, Angelo MM, Dring LG, Lancaster R, Smith RL (1979) The metabolism of [14C] debrisoquine in man. Br J Clin Pharmacol 7:257-266
27. Jacqz-Aigrain E, Menard Y, Popon M, Mathieu H (1989) Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection. J Chromatogr 495:361-363
28. Kim RB (2002) MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 12:425-427
29. Kim RB, O'Shea D, Wilkinson GR (1995) Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 57:645-655
30. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL (1982) Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analysed in cryopreserved lymphocytes. Cancer Res 42:5030-5037
31. Leathart JBS, London SJ, Adams JD, Idle JR, Daly AK (1998) CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians. Pharmacogenetics 8:529-542
32. Lennard MS (1985) Quantitative-analysis of metoprolol and 3 of its metabolites in urine and liver-microsomes by high-performance liquid-chromatography. J Chromatogr 342:199-205
33. Liu ZR, Mortimer O, Smith CAD, Wolf CR, Rane A (1995) Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism. Br J Clin Pharmacol 39:77-80
34. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet ii: 584-586
35. Milland J, Christiansen D, Thorley BR, McKenzie IFC, Loveland BE (1996) Translation is enhanced after silent nucleotide substitutions in A+T-rich sequences of the coding region of CD46 cDNA. Eur J Biochem 238:221-230
36. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 5 '-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808
37. Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874-879
38. Patel M, Tang BK, Grant DM, Kalow W (1995) Interindividual variability in the glucuronidation of (S)-oxazepam contrasted with that of (R)-oxazepam. Pharmacogenetics 5:287-297
39. Playfer JR, Eze LC, Bullen MF, Evans DAP (1976) Genetic polymorphism and inter-ethnic variability of plasma paraoxonase activity. J Med Genet 13:337-342
40. Price RA, Cox NJ, Spielman RS, Van Loon JA, Maidak BL, Weinshilboum RM (1988) Inheritance of human platelet thermolabile phenol sulphotransferase (TLPST) activity. Genet Epidemiol 5:1-15
41. Price RA, Spielman RS, Lucena AL, Van Loon JA, Maidak BL, Weinshilboum RM (1989) Genetic polymorphism for human platelet thermostable phenol sulphotransferase (TSPST) activity. Genetics 122:905-914
42. Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, Carpenter SP (1997) Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metab Dispos 25:1429-1435
43. Ravnik-Glavac M, Glavac D, Dean M (1994) Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic-fibrosis gene. Hum Mol Genet 3:801-807
44. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90: 1225-1229
45. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
46. Sachse C, Brochmoller J, Bauer S, Roots I (1999) Functional significance of a C→A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449
47. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Gamer RC, Boobis AR, Wolf CR, Gooderham NJ (2003) Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55:68-76
48. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56
49. Seidegard J, Pero RW (1985) The hereditary transmission of high glutathione transferase-activity towards trans-stilbene oxide in human mononuclear leukocytes. Hum Genet 69:66-68
50. Shimoda K, Noguchi T, Ozeki Y, Morita S, Shibasaki M, Someya T, Takahashi S (1995) Metabolism of clomipramine in a Japanese psychiatric population - hydroxylation, desmethylation, and glucuronidation. Neuropsychopharmacology 12:323-333
51. Sinues B, Saenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, Mayayo E (1999) Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiol Biomarkers Prev 8:159-166
52. Streetman DS, Bertino JS, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo phenotyping probes. Pharmacogenetics 10:187-216
53. Syvanen AC (1999) From gels to chips: "minisequencing" primer extension for analysis of point mutations and single nucleotide polymorphisms. Hum Mutat 13:1-10
54. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL (1994) Use of midazolam as a human cytochrome-P450 3a probe. I. In-vitro in-vivo correlation in liver-transplant patients. J Pharmacol Exp Ther 271:549-556
55. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with the use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403-411
56. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ (1990) The erythromycin breath test as a predictor of cyclosporine blood-levels. Clin Pharmacol Ther 48:120-129
57. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36:773-780
58. Weinshilboum RM, Raymond FA (1977) Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am J Hum Genet 29:125-135
59. Weinshilboum R, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651-662
60. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Comm 259:201-205
61. Whittaker M, Britten JJ, Dawson PJG (1983) Comparison of a commercially available assay system with two reference methods for the determination of cholinesterase variants. Clin Chem 29:1746-1751
62. Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17:439-474
63. Yue QY, Iselius L, Sawe J (1997) Indices and graphical approaches for the detection of interindividual and interethnic variations in codeine metabolism. Br J Clin Pharmacol 44: 239-244
64. Zhiri A, Mayer HA, Michaux V, Wellmanbednawska M, Siest G (1986) 6-Beta-hydroxycortisol in serum and urine as determined by enzyme-immunoassay on microtitre plates. Clin Chem 32:2094-2097